tbuckley/cabot-search huggingface dataset:
Unsuspected Muscular Radionuclide Uptake Due to Chronic Muscular Injury Contracted During Sports Activity
Authors: JAN ROLAND, LUC HOUBEN, JOHAN VANDEVIVERE
Journal: Clinical Nuclear Medicine (1997)

Increased soft-tissue uptake is commonly encountered in metastases, infarction, vascular calcification, myositis ossificans, hemangiomas. In addition, injured muscles and rhabdomyolysis have an affinity for bone-seeking radiopharmaceuticals. Matin and co-workers even correlated the intensity of muscular tracer uptake with complaints in "ultra-marathon" runners. In this patient, however, the very intense muscular uptake, caused by repeated sport-induced injuries of a rather unusual origin, did not correlate with the complaints. Also, our case illustrates that even children are at risk for unsuspected traumatic lesions, contracted during sports or physical activity.
An FDG Positron Emission Tomographic Study in a Case of Gastrointestinal Stromal Tumor
Authors: SUBHASH CHANDER, ESER LAY ERGUN, ANTHONY F. SHIELDS
Journal: Clinical Nuclear Medicine (2003)

CHANDER, SUBHASH M.D.; LAY ERGUN, ESER M.D.; SHIELDS, ANTHONY F. M.D., PH.D. Author Information
Abstract LB-420: Long circulating 18F-labeled liposomes for PET imaging
Authors: Biying Xu, F Basuli, H Wu, A. Salima, A Opina, K Lane, G. L. Griffiths, E. Jagoda, M Green, J. Seidel, P. Choyke
Journal: Cancer Research (2012)

Abstract Liposomes are lipid nanoparticles comprised of phospholipid bilayers with an aqueous interior. They have emerged as promising multi-modality imaging agents and engender significant interest as drug delivery vehicles, e.g. doxorubicin liposomes. Although a number of methods for radiolabeling liposomes with various radionuclides have been developed, 18F is the most useful for PET imaging. In this study, preformed maleimide-PEG functionalized liposomes with a mean diameter of 70 nm were obtained by sonication of a lipid mixture consisting of DPPC, cholesterol, and DSPE-PEG2000-Mal (61:30:9) in acetate buffer (pH 6.5) followed by extrusion. 18F labeled 2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)ethanethiol was prepared, followed by conjugation with the maleimide-PEG functionalized liposome in 0.1M acetate buffer (0.1% EDTA), pH 6.5-8.0. Liposome sizes did not differ significantly before and after the 18F labeling. The overall radiochemical yield of the reaction was 10-25% (n= 12, uncorrected) in a 180 minute radiolabeling time. Micro PET imaging of rats was done at various times, up to 4 hrs, following IV injection of the 18F liposomes and their bio-distribution was also investigated. Our imaging studies with 18F liposomes appear comparable to images from previously described labeling methods with 18F liposomes remaining in the blood pool at 4 hrs. Our results indicate that this will allow the ready availability of 18F liposomes for vascular imaging and also potentially for cancer imaging. Research Support: This study was funded by the intramural program of the National Institutes of Health. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-420. doi:1538-7445.AM2012-LB-420
TRANSCATHETER AORTIC VALVE REPLACEMENT RESULTS IN SIGNIFICANT REVERSE REMODELING IN PATIENTS WITH LEFT VENTRICULAR DILATION: A REPORT FROM THE PARTNER I TRIAL
Authors: Melissa A. Daubert, Philippe Pibarot, Rebecca Hahn, Neil Weissman, William Stewart, Justina Wu, Sammy Elmariah, Brian Lindman, E. Murat Tuzcu, Rakesh Suri, Ke Xu, Martin Leon, Pamela Douglas
Journal: Journal of the American College of Cardiology (2015)
Failure to detect fabricated posttraumatic stress disorder with the use of the MMPI in a clinical population
Authors: S T Perconte, A J Goreczny
Journal: American Journal of Psychiatry (1990)

The authors attempted to replicate previous studies that used the Frequency (F) scale and the posttraumatic stress disorder (PTSD) subscale of the MMPI to discriminate Vietnam veterans with PTSD from well-adjusted veterans and mental health professionals who feigned symptoms of PTSD. Profiles of veterans with PTSD were compared to those of veterans with non-PTSD psychiatric disorders and veterans with fabricated PTSD symptoms who sought treatment. Discriminant analysis of F scale and PTSD subscale scores correctly identified only 43.59% of the subjects, thus failing to support use of the MMPI in detecting fabricated symptoms of PTSD in a clinical population.
Abstract 2435: Chromogranin A and its N-terminal fragment affect the metastatic potential of circulating tumor cells in mice
Authors: Eleonora Dondossola, Luca Crippa, Barbara Colombo, Elisabetta Ferrero, Angelo Corti
Journal: Cancer Research (2011)

Abstract Chromogranin A (CgA) is an acidic glycoprotein present within secretory vesicles of many normal and neoplastic endocrine and neuroendocrine cells. CgA is abnormally released in circulation in patients with neuroendocrine tumors and non neuroendocrine tumors, as in a subpopulation of patients with non small cell lung cancer (NSCLC), with important prognostic implications. We have previously demonstrated that CgA can preserve the barrier function of the vascular endothelium. Since hematogenous metastasis requires the seeding of malignant cancer cells in circulation, followed by cell extravasation and colonization of distant organs, we investigated the role of CgA on tumor cell extravasation and lung colony formation. We show that normal levels of endogenous CgA can reduce the number of lung colonies from mammary TS/A adenocarcinoma cells injected into the venous circulation of mice. Administration of omeprazole, a drug commonly used in the treatment of acid-peptic disorders, increased the blood levels of CgA and further inhibited the development of lung colonies in a CgA-dependent manner. Furthermore, administration of recombinant CgA or its N-terminal fragment (called vasostatin-1, VS-1) reduced the metastatic potential of circulating mammary TS/A adenocarcinoma and B16-F10 melanoma cells. Studies on the mechanism of action showed that CgA and VS-1 can inhibit the transendothelial migration of cancer cells, by preserving the VE-cadherin-dependent endothelial barrier function. These findings suggest that endogenous CgA can play a role as a modulator of the metastatic potential of circulating tumor cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2435. doi:10.1158/1538-7445.AM2011-2435
Case 13-2010
Authors: Neal S. LeLeiko, Michael S. Gee, Peter M. Sadow
Journal: New England Journal of Medicine (2010)

An 18.5-month-old girl was seen in the pediatric gastroenterology clinic of this hospital because of watery diarrhea and poor weight gain. The child had been healthy until 12 months of age, when chronic watery diarrhea developed. Six months later, her weight had decreased to the fourth percentile for her age. Extensive studies of stool, ultrasonography of the abdomen, and upper and lower endoscopic examinations were normal. A sweat test was interpreted as borderline. A diagnostic test result was received.
Abstract 293: Regulation of inhibitor of differentiation 1 (Id1) by PKC signaling in the intestinal epithelium
Authors: Fang Hao, Marybeth A. Pysz, Kristin N. Haas, Kathryn J. Curry, Thomas R. Vollmer, Adrian R. Black, Jennifer D. Black
Journal: Cancer Research (2010)

Abstract Increasing evidence supports a role for protein kinase C (PKC) signaling in regulation of intestinal epithelial self-renewal, and alterations in PKC isozyme expression/activity have been broadly linked to intestinal carcinogenesis. PKCα, which exhibits growth inhibitory and tumor suppressor properties in the intestine, is lost early during intestinal tumor development. To gain further insight into the tumor suppressive effects of PKCα signaling, we explored the consequences of restoration of PKCα expression in DLD-1 human colon cancer cells by microarray analysis. The most downregulated known gene in PKCα-expressing DLD-1 cells was inhibitor of differentiation 1 (Id1), a member of the Id family of dominant negative antagonists of bHLH transcription factors that has cell cycle stimulatory functions and has been associated with tumorigenesis in a number of systems. Suppression of Id1 protein by PKCα in colon cancer cells was confirmed by Western blot analysis in a panel of cell lines including DLD-1, HCT116, FET, FET/DNR, and GEO. Notably, activation of PKC/PKCα in non-transformed IEC-18 intestinal crypt cells also resulted in rapid and profound downregulation of Id1 mRNA and protein, pointing to a role for PKCα in Id1 regulation in the normal intestinal epithelium. PKC-induced suppression of Id1 was found to occur via an ERK/MAPK-dependent, PI3K-independent mechanism. Manipulation of Id1 levels in normal and transformed intestinal cells demonstrated its ability to affect two key cell cycle targets of PKCα, the potent mitogen cyclin D1 and the cdk inhibitor p21Waf1/Cip1. Knockdown of Id1 consistently decreased steady-state levels of cyclin D1, while overexpression of the factor resulted in reduced levels of p21Waf1/Cip1. Thus, Id1 appears to control the expression of important cell cycle regulators in intestinal cells. Immunohistochemical analysis of normal intestinal mucosa further demonstrated that PKCα activation, which occurs precisely at the point of growth arrest in the mid/upper crypt, coincides with marked downregulation of Id1 in vivo. Conversely, loss of PKCα in intestinal tumors is associated with Id1 overexpression. Ongoing studies are focused on delineating the link between the tumor suppressor functions of PKCα and its inhibitory effects on Id1 expression in intestinal cells. Supported by NIH grants DK54909, DK60632, CA16506, and CA113048. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 293.
AB0551 Long-term effects of etanercept treatment on vascular function and lipid parameters in ankylosing spondylitis
Authors: N. Bodnár, G. Kerekes, E. Végh, K. Gulyás, F. Balázs, L. Pogácsás, I. Pál, Z. Szekanecz, S. Szántó
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Cardiovascular (CV) morbidity and mortality are increased in patients with arthritides, including ankylosing spondylitis (AS). Biologics may influence vascular function and lipids in AS, however a lot more information has become available in rheumatoid arthritis. In addition, most studies have been short-term and less information has become available on etanercept (ETN) in comparison to other biologics, such as infliximab. <h3>Objectives</h3> We wished determine vascular damage and lipid profile in AS and the effects of ETN on common carotid intima-media thickness (ccIMT), brachial artery flow-mediated, endothelium-dependent vasodilatation (FMD) and the arterial stiffness marker pulse wave velocity (PWV) in context with laboratory assessments after 12 months of biological therapy. <h3>Methods</h3> Seventeen AS patients (14 males, 3 females) with a mean age of 42.6 years and a mean disease duration of 7.2 years were included. 50mg weekly ETN therapy was administered and patients were assessed at baseline and after 12 months of treatment. Brachial and carotid ultrasonography was performed to determine FMD, ccIMT and PWV, respectively. We also assessed immunological, inflammatory and metabolic laboratory markers. <h3>Results</h3> At baseline, meanccIMT was 0.47 mm (normal range: 0.4-0.9 mm), mean FMD was 6,9% (normal: &gt;10%) and the mean PWV was 6.4 m/s (normal range: 4-20m/s). At baseline, a significant inverse correlation was observed between CRP and HDL-C levels (R=-0.518, p=0.033). ccIMT strongly correlated with BASDAI R=0.881, p=0.001). After 12 months of anti-TNF treatment, BASDAI (from 6.14 to 1.25; p&lt;0.001), CRP (from 13.4 to 2.3 mg/l; p=0.002). FMD (from 6.9% to 9.3%; p=0.01) and PWV (from 6.4 to 5.4 m/sec, p=0.045) significantly improved, while ccIMT showed no change. There have been no significant changes in lipid levels. <h3>Conclusions</h3> In patients with AS, FMD, a marker of endothel dysfunction and PWV, a marker of arterial stiffness significantly improved after 12 months of anti-TNF treatment with ETN. These beneficial vascular changes were associated with improved disease activity. ccIMT may require more time to improve. <h3>Disclosure of Interest</h3> None Declared
A Simple Chromatographic Screening Test for the Detection of Disorders of Amino Acid Metabolism
Authors: Mary L. Efron, Dean Young, Hugo W. Moser, Robert A. MacCready
Journal: New England Journal of Medicine (1964)

GUTHRIE'S1 2 3 recently introduced bacterial inhibition assay provides a simple and practical mass screening method for phenylketonuria. Although phenylketonuria is the best known it is by no means the only inborn error of amino acid metabolism characterized by the accumulation of large amounts of one or more amino acids in the blood. Ten such disorders have been reported in the literature.4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 These are listed in Table 1, together with their most striking clinical features. Several others are known to be under investigation. All except tyrosinosis have been associated with mental retardation in some if not all persons affected.This report describes . . .
Prophylactic Red-Cell Transfusions in Pregnant Patients with Sickle Cell Disease
Authors: Mabel Koshy, Laurence Burd, David Wallace, Atef Moawad, Joseph Baron
Journal: New England Journal of Medicine (1988)

Prophylactic blood transfusion has come to be regarded as necessary in the treatment of patients with sickle cell disease during pregnancy. Because of the risks associated with blood products and reports of successful outcomes without the use of blood transfusion, we conducted a prospective randomized controlled study of this issue. Seventy-two pregnant patients with sickle cell anemia were randomly assigned to one of two treatment groups: 36 received prophylactic transfusions of frozen red cells, and 36 received red-cell transfusions only for medical or obstetric emergencies. Twenty-eight patients with sickle cell anemia who did not qualify for randomization (mainly because they had other medical disorders), 66 with sickle cell–hemoglobin C disease, and 23 with sickle cell–betathalassemia were also followed and received transfusions only for emergencies. There was no significant difference in perinatal outcome between the offspring of mothers with sickle cell disease who were assigned to treatment with prophylactic transfusions and those who were not (15 vs. 5 percent). The occurrence of a perinatal death in a previous pregnancy and the presence of twins in the present pregnancy were two major risk factors for an unfavorable outcome; when they were present, perinatal mortality was 50 percent. Perinatal mortality was somewhat higher in the two groups that were randomized than in the three groups that were not. Prophylactic transfusion significantly reduced the incidence of painful crises of sickle cell disease (P<0.01) and substantially reduced the cumulative incidence of other complications of this disorder (P = 0.07). Other medical and obstetric complications occurred with nearly equal frequency in the two randomized groups. Increases in costs, the number of hospitalizations, and the risk of alloimmunization were disadvantages of prophylactic transfusion. We conclude that the omission of prophylactic red-cell transfusion will not harm pregnant patients with sickle cell disease or their offspring. (N Engl J Med 1988; 319: 1447–52.)
419 QUANTITATIVE SERUM HEPATITIS B SURFACE ANTIGEN IMPROVES PREDICTABILITY OF HBVDNA SEROCLEARANCE BUT NOT HBeAg SEROCLEARANCE IN CHRONIC HEPATITIS B PATIENTS
Authors: J. Liu, H.-I. Yang, M.-H. Lee, C.-L. Jen, S.-N. Lu, L.-Y. Wang, S.-L. You, U.H. Iloeje, C.K. Hsiao, C.-J. Chen
Journal: Journal of Hepatology (2013)
AB0566 Improved efficacy of rituximab in rheumatoid arthritis when administered regularly at six-month intervals – data from the serbian registry (NARASS)
Authors: P. Ostojic, N. Damjanov, A. Dimic, D. Stefanovic, M. Lazarevic, T. Ilic, S. Zivojinovic
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rituximab is the only currently available B-cell depleting agent, licensed for use in treatment of rheumatoid arthritis (RA).The optimal therapeutic strategy that would give an answer to the question when is the best moment to repeat a course of rituximab, has not yet been clearly defined. In addition to strictly controlled randomized studies, registers show the effectiveness of different therapeutic strategies applied in daily clinical practice. <h3>Objectives</h3> To assess the efficacy of rituximab in RA when administered every six months in comparison to a longer period between two courses, according to data from the Serbian registry of RA patients (NARASS). <h3>Methods</h3> 161 RA patients, treated with rituximab are followed to date in NARRAS. Forty of them (33 women and 7 men, mean age 52 years), who received at least three courses of the drug were selected and analyzed. They were divided into two subgroups: subgroup I (SG<sub>1</sub>) - 26 (65%) patients who received rituximab every six months, and subgroup II (SG<sub>2</sub>) - 14 (35%) patients with a time period of seven months or more between two courses. Disease activity score (DAS<sub>28</sub>) was assessed before each course and six months after the third course of rituximab, and compared between two subgroups of patients. The analysis of variance (ANOVA) and Student's T-test were used for statistical analyses of data. <h3>Results</h3> Mean disease duration before diagnosis of RA in two subgroups of patients did not differ significantly (SG<sub>1</sub>: SG<sub>2</sub>=12.6: 17.5 months, p=0.85), as well as disease duration from diagnosis to beginning of treatment with rituximab (SG<sub>1</sub>: SG<sub>2</sub> =133.1: 123.6 months, p=0.71). The mean time period between two courses of rituximab for patients in SG<sub>1</sub> was 6.2 months and for patients in SG<sub>2</sub> 8.9 months. Analyzing the data for the whole group of 40 patients we have noticed a statistically significant decrease in disease activity six months after the third course of rituximab, compared to the period before treatment (DAS<sub>28</sub> index decreased from 5.87 to 4.47, p&lt;0.001). The effectiveness of rituximab on disease activity was better in SG<sub>1</sub> compared to SG<sub>2</sub> - mean DAS<sub>28</sub> decreased significantly (p=0.002) from 6.30 (before treatment) to 4.31 (six months after the third course) in SG<sub>1</sub>, and from 5.12 to 4.80 in SG<sub>2</sub> (p=0.057). <h3>Conclusions</h3> The efficacy of rituximab is better when patients are retreated regularly at six-month intervals, compared to patients who receive the drug with a longer time period between the courses <h3>Disclosure of Interest</h3> None Declared
Savile committed 50 criminal offences on 14 hospital sites, say police
Authors: Z. Kmietowicz
Journal: BMJ (2013)

Thirteen hospitals and a hospice have been named in a police report as playing host to the television presenter Jimmy Savile’s abuse of children over more than 50 years.

Leeds General Infirmary and Stoke Mandeville Hospital were the main locations of Savile’s alleged offending, with a total of 38 crimes reported to have taken place at the two sites between 1965 and 1995.

So far 214 criminal offences have been formally recorded against Savile, including 126 indecent acts and 34 offences of rape or penetration. Of these alleged offences, 50 were reported as taking place on hospital and hospice premises.

The report, Giving Victims a Voice , says that 450 people have come forward to allege incidents against Savile between 1955 and 2009. Most of his victims (73%) were children (under 18 years old), and 82% were female.1 The peak of the offending that has been reported was from 1966 to 1976, when Savile …
Abstract 3333: Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma
Authors: Seung-Ki Kim, Seung Ah Choi, Sung-Kyun Hwang, Kyu-Chang Wang, Byung-Kyu Cho, Ji Hoon Phi, Ji Yeoun Lee, Hee Won Jung, Do-Hun Lee
Journal: Cancer Research (2010)

Abstract Mesenchymal stem cells (MSCs) have an extensive migratory capacity for gliomas, which is comparable to that of neural stem cells. Among the various types of MSCs, human adipose tissue-derived MSCs (hAT-MSC) emerge as one of the most attractive vehicles for gene therapy because of their high throughput, lack of ethical concerns, and availability and ease of isolation. We evaluated the therapeutic potential and safety of genetically engineered hAT-MSCs encoding the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) against brainstem gliomas. hAT-MSCs were isolated from human fat tissue, characterized, and transfected with TRAIL using nucleofector. The therapeutic potential of TRAIL-producing hAT-MSCs (hAT-MSC.TRAIL) was confirmed using in vitro and in vivo studies. The final fate of injected hAT-MSCs was traced in long-survival animals. The characterization of hAT-MSCs revealed the expression of MSC-specific cell-type markers and their differentiation potential into neuronal lineage. Short-term outcomes included a 56.3% reduction of tumor volume (P &amp;lt; 0.001) with increased apoptosis (3.03-fold, P &amp;lt; 0.05) in animals treated with hAT-MSC.TRAIL compared with the control groups. Long-term outcomes included a significant survival benefit in the hAT-MSC.TRAIL-treated group (26 days of median survival in the control group vs 84 days in the hAT-MSC.TRAIL-treated group, P &amp;lt; 0.0001), without any evidence of mesenchymal differentiation in vivo. Our study demonstrated the therapeutic efficacy and safety of nonvirally engineered hAT-MSCs against brainstem gliomas. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3333.